Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Global Development, Inc.
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients aged 50 years or greater diagnosed with GA inside and/or outside of the fovea who completed Study ISEE2008 (GATHER2) through the Month 24 visit on study treatment.
Patient must provide new written informed consent for this OLE trial prior to participation.
Patient must have the ability to return for all trial visits for the duration of the 18-month trial.
You may not be if
Patient did not complete Study ISEE2008 (GATHER2) through the Month 24 visit on study treatment (either avacincaptad pegol or Sham).
Patient did not enroll into this OLE trial within the 90 day enrollment period.
Patient who is pregnant or nursing.
Clareo Health | Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
